Jazz Pharmaceuticals
Stock Forecast, Prediction & Price Target
Jazz Pharmaceuticals (JAZZ) stock Price Target by analysts
$182.75
Potential upside: 52.60%
Jazz Pharmaceuticals price prediction
What is Jazz Pharmaceuticals stock analysts` prediction?
Jazz Pharmaceuticals stock forecast: Based on 4 Wall Street analysts` predicted price targets for Jazz Pharmaceuticals in the last 3 months, the avarage price target is $182.75, with a high forecast of $NaN. The average price target represents a 52.60% change from the last price of $119.75.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Jazz Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Jazz Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Akash Tewar Jefferies | 0% 0/1 | 10 months ago | $160 33.61% upside | $125.1 | StreetInsider | Previous targets (0) |
Joel Beatty Robert W. Baird | 0% 0/1 | 10 months ago | $162 35.28% upside | $122 | StreetInsider | Previous targets (0) |
Daniel Busb RBC Capital | 0% 0/2 | 11 months ago | $179 49.47% upside | $113.1 | StreetInsider | Previous targets (1) |
Annabel Samimy Stifel Nicolaus | 0% 0/2 | 12 months ago | $230 92.06% upside | $105.22 | StreetInsider | Previous targets (1) |
Andrea Tan Goldman Sachs | 0% 0/1 | about 1 year ago | $169 41.12% upside | $104.48 | StreetInsider | Previous targets (0) |
Daniel Busb RBC Capital | 0% 0/2 | over 1 year ago | $176 46.97% upside | $110.31 | StreetInsider | Previous targets (1) |
David Amsellem Piper Sandler | 0% 0/2 | over 1 year ago | $188 56.99% upside | $124.79 | StreetInsider | Previous targets (1) |
Unknown Goldman Sachs | N/A | over 2 years ago | $190 58.66% upside | $150.07 | Benzinga | N/A |
Unknown RBC Capital | N/A | almost 3 years ago | $207 72.86% upside | $149.9 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | almost 3 years ago | $192 60.33% upside | $149.9 | Benzinga | N/A |
David Amsellem Piper Sandler | 0% 0/2 | about 3 years ago | $193 61.16% upside | $142.91 | Pulse 2.0 | Previous targets (1) |
Ashwani Verma UBS | 0% 0/1 | about 3 years ago | $194 62.00% upside | $141.59 | TheFly | Previous targets (0) |
Ami Fadia Needham | 0% 0/1 | over 3 years ago | $215 79.54% upside | $152.9 | Pulse 2.0 | Previous targets (0) |
Greg Fraser Truist Financial | 0% 0/1 | over 3 years ago | $200 67.01% upside | $139.13 | TheFly | Previous targets (0) |
Annabel Samimy Stifel Nicolaus | 0% 0/2 | over 3 years ago | $210 75.36% upside | $144.3 | StreetInsider | Previous targets (1) |
Aaron Gal Bernstein | 0% 0/1 | over 3 years ago | $175 46.13% upside | $131.01 | StreetInsider | Previous targets (0) |
Jason Gerberry Bank of America Securities | 0% 0/1 | almost 4 years ago | $193 61.16% upside | $136.32 | StreetInsider | Previous targets (0) |
Brandon Folkes Cantor Fitzgerald | 0% 0/1 | almost 4 years ago | $210 75.36% upside | $136.91 | StreetInsider | Previous targets (0) |
Navann Ty Citigroup | 0% 0/1 | almost 4 years ago | $200 67.01% upside | $128.08 | TheFly | Previous targets (0) |
Balaji Prasad Barclays | 0% 0/1 | about 4 years ago | $250 108.76% upside | $177.3 | TheFly | Previous targets (0) |
Esther Rajavelu UBS | 0% 0/1 | about 4 years ago | $234 95.40% upside | $177.28 | StreetInsider | Previous targets (0) |
Ken Cacciatore Cowen & Co. | 0% 0/1 | over 4 years ago | $200 67.01% upside | $176.1 | StreetInsider | Previous targets (0) |
Jazz Pharmaceuticals Financial Estimates
Jazz Pharmaceuticals Revenue Estimates
Jazz Pharmaceuticals EBITDA Estimates
Jazz Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $3.09B N/A | $3.65B 18.26% | $3.83B 4.77% | Avg: $4.36B Low: $4.13B High: $4.62B avg. 13.91% | Avg: $4.59B Low: $4.40B High: $4.78B avg. 5.21% | Avg: $4.75B Low: $4.55B High: $4.94B avg. 3.38% | Avg: $4.96B Low: $4.76B High: $5.16B avg. 4.59% |
Net Income
% change YoY
| $-328.95M N/A | $-214.13M 34.90% | $414.83M 293.72% | Avg: $597.68M Low: $284.66M High: $1.03B avg. 44.07% | Avg: $648.97M Low: $463.18M High: $965.68M avg. 8.58% | Avg: $1.70B Low: $1.61B High: $1.79B avg. 162.65% | Avg: $1.81B Low: $1.71B High: $1.90B avg. 6.25% |
EBITDA
% change YoY
| $696.04M N/A | $1.11B 59.67% | $1.28B 15.86% | Avg: $1.53B Low: $1.45B High: $1.63B avg. 19.53% | Avg: $1.61B Low: $1.55B High: $1.68B avg. 5.21% | Avg: $1.67B Low: $1.60B High: $1.74B avg. 3.38% | Avg: $1.75B Low: $1.67B High: $1.82B avg. 4.59% |
EPS
% change YoY
| -$5.51 N/A | -$3.42 37.93% | $6.95 303.21% | Avg: $8.55 Low: $3.95 High: $14.35 avg. 23.07% | Avg: $8.63 Low: $6.43 High: $13.4 avg. 0.88% | Avg: $23.65 Low: $22.37 High: $24.89 avg. 174.10% | Avg: $25.13 Low: $23.77 High: $26.45 avg. 6.25% |
Operating Expenses
% change YoY
| $2.48B N/A | $2.60B 4.96% | $2.82B 8.18% | Avg: $1.65B Low: $1.56B High: $1.75B avg. -41.36% | Avg: $1.73B Low: $1.66B High: $1.80B avg. 5.21% | Avg: $1.79B Low: $1.72B High: $1.87B avg. 3.38% | Avg: $1.88B Low: $1.80B High: $1.95B avg. 4.59% |
FAQ
What is Jazz Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 55.39% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is 284.66M, average is 597.68M and high is 1.03B.
What is Jazz Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 6.77% in 2025-2028.
We have gathered data from 16 analysts. Their low revenue estimate is $4.13B, average is $4.36B and high is $4.62B.
What is Jazz Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 51.07% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is $3.95, average is $8.55 and high is $14.35.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Jazz Pharmaceuticals stock. The most successful analyst is Akash Tewar.